Can Finland become the leader in pharmaceutical development? Pharmaceutical industry has an opportunity for renewal

“The pharmaceutical industry, which is also a significant export sector, now has an opportunity for growth in Finland. Society as a whole benefits from innovation in the pharmaceutical sector, and domestic production is important for security of supply,” says Liisa Hurme, SVP, Global Operations at Orion.

Read more
Orion Now 

Yrityskylä introduces an increasing number of young people to working life

Yrityskylä for sixth-graders in Espoo will resume face-to-face education in October 2021. As before, Orion will be helping young people gain their first experiences of working life and learn about society. During the current school year, Yrityskylä will be expanded, and its operations will be further diversified.

Read more
Orion Now 

Pain patients find relief through digital therapy

Artificial intelligence accelerates drug development

New approaches bring hope to people with neurological disorders

One person in six has a neurological disorder but treatments are difficult to find. Now new approaches are bringing hope to patients.

Read more
Research 

Orion and Alligator Bioscience announce immuno-oncology research collaboration and license agreement

The goal of the agreement is to discover and develop together new bispecific antibody cancer therapeutics.

Read more

Orion signs European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone

Carbon Footprint Assessment of Orion’s Dry Powder Inhalers

Research areas

Orion develops new pharmaceuticals in three therapy areas. Orion’s pharmaceutical R&D focuses on the central nervous system, cancer and critical care, and inhalable Easyhaler® pulmonary drugs. Orion also develops veterinary and generic drugs. 

Read more
Research 

Orion's R&D Pipeline

Scientific publications

A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.

Read more

Financial reviews and presentations

Orion published Interim Report for January–September 2021 on Wednesday, 20 October 2021. The report and related presentation material as well as webcast recording are available here.

Read more
Orion Group 

AGM 2021

The Annual General Meeting of Orion Corporation was held on Thursday 25 March 2021 at Orion's Head Office in Espoo. The decisions and related material are available here.

Read more

Financial Statements

Orion Group's Financial Statement documents for 2020 are available here.

Read more

Press Releases

10/5/2021 Orion publishes Interim Report for January–September 2021 on Wednesday 20 October 2021
8/18/2021 Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement
8/17/2021 Orion will remain as the owner of pharmaceutical manufacturing plant in Kuopio, Finland
8/3/2021 Orion Corporation signs European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone

Stock Exchange Releases

10/20/2021 Orion Group Interim Report 1–9/2021
10/8/2021 Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
10/8/2021 Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
9/17/2021 Successor plan of the President and CEO of Orion

Working in the pharmaceutical industry

Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.

Read more
Careers at Orion 

Orion is one of the most popular employers in Finland

Orion was ranked 17th in the Top 50 Most Attractive Employers in Finland in Academic Work's Young Professional Attraction Index (YPAI) 2021 survey of young professionals and graduate students.

Read more

Open Vacancies

See all open vacancies here.

Read more

Contract Manufacturing

Critical Care

One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.

Read more

For healthcare professionals